165 related articles for article (PubMed ID: 19368139)
1. Review. Current role and future perspectives of hyperthermia for prostate cancer treatment.
Baronzio G; Gramaglia A; Fiorentini G
In Vivo; 2009; 23(1):143-6. PubMed ID: 19368139
[TBL] [Abstract][Full Text] [Related]
2. [Local hyperthermia in prostate cancer].
Bichler KH; Strohmaier WL; Flüchter SH; Nelde HJ; Wilbert DM
Urologe A; 1991 May; 30(3):196-203. PubMed ID: 1871941
[TBL] [Abstract][Full Text] [Related]
3. [Thermochemotherapy of prostatic cancer].
Hirai M
Hinyokika Kiyo; 1991 Aug; 37(8):833-6. PubMed ID: 1720274
[TBL] [Abstract][Full Text] [Related]
4. Survival outcomes in men receiving androgen-deprivation therapy as primary or salvage treatment for localized or advanced prostate cancer: 20-year single-centre experience.
DiBlasio CJ; Malcolm JB; Hammett J; Wan JY; Aleman MA; Patterson AL; Wake RW; Derweesh IH
BJU Int; 2009 Nov; 104(9):1208-14. PubMed ID: 19388987
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional nanoparticles for prostate cancer therapy.
Salvador-Morales C; Gao W; Ghatalia P; Murshed F; Aizu W; Langer R; Farokhzad OC
Expert Rev Anticancer Ther; 2009 Feb; 9(2):211-21. PubMed ID: 19192959
[TBL] [Abstract][Full Text] [Related]
6. [Histopathologic changes due to combination of androgen deprivation and transurethral microwave thermotherapy in patients with localized prostate cancer].
Suzuki R; Jujo Y; Koshiba K; Hoshiai O; Endo T; Aihara M; Nakajo H; Ohori M
Hinyokika Kiyo; 2009 Feb; 55(2):79-85. PubMed ID: 19301612
[TBL] [Abstract][Full Text] [Related]
7. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
Vis AN; Schröder FH
BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
[TBL] [Abstract][Full Text] [Related]
8. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma.
Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821
[TBL] [Abstract][Full Text] [Related]
9. Re: Current status of local salvage therapies following radiation failure for prostate cancer.
Johannsen M; Loening SA; Deger S
J Urol; 2005 Sep; 174(3):1152-3; author reply 1153. PubMed ID: 16094089
[No Abstract] [Full Text] [Related]
10. Interstitial hyperthermia using thermoseeds in combination with conformal radiotherapy for localized prostate cancer.
Deger S; Böhmer D; Roigas J; Türk I; Budach V; Loening SA
Front Radiat Ther Oncol; 2002; 36():171-6. PubMed ID: 11842749
[No Abstract] [Full Text] [Related]
11. Bisphenol A may reduce the efficacy of androgen deprivation therapy in prostate cancer.
Hess-Wilson JK
Cancer Causes Control; 2009 Sep; 20(7):1029-37. PubMed ID: 19370395
[TBL] [Abstract][Full Text] [Related]
12. [Treatment alternatives of the locally advanced prostate cancer].
Pacík D
Cas Lek Cesk; 2005; 144 Suppl 2():39-44. PubMed ID: 16277184
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological behavior of single focus prostate adenocarcinoma.
Rice KR; Furusato B; Chen Y; McLeod DG; Sesterhenn IA; Brassell SA
J Urol; 2009 Dec; 182(6):2689-94. PubMed ID: 19836800
[TBL] [Abstract][Full Text] [Related]
14. Prostate cancer and urinary incontinence.
Parsons BA; Evans S; Wright MP
Maturitas; 2009 Aug; 63(4):323-8. PubMed ID: 19615834
[TBL] [Abstract][Full Text] [Related]
15. Clinical implications of neuroendocrine differentiation in prostate cancer.
Nelson EC; Cambio AJ; Yang JC; Ok JH; Lara PN; Evans CP
Prostate Cancer Prostatic Dis; 2007; 10(1):6-14. PubMed ID: 17075603
[TBL] [Abstract][Full Text] [Related]
16. [Microwave thermotherapy for benign prostatic hyperplasia. A survey of a Cochrane review].
Andersen M; Walter S
Ugeskr Laeger; 2009 Aug; 171(33):2281-4. PubMed ID: 19732507
[No Abstract] [Full Text] [Related]
17. [Localized transrectal hyperthermia in the treatment of obstructive manifestations of prostatic adenoma. Review of the literature and personal experience].
Zerbib M; Conquy S; Steg A; Martinache PR; Flam T; Debré B
J Urol (Paris); 1992; 98(2):89-92. PubMed ID: 1431190
[TBL] [Abstract][Full Text] [Related]
18. Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression.
Johnke RM; Edwards JM; Evans MJ; Nangami GN; Bakken NT; Kilburn JM; Lee TK; Allison RR; Karlsson UL; Arastu HH
In Vivo; 2009; 23(5):827-33. PubMed ID: 19779119
[TBL] [Abstract][Full Text] [Related]
19. Optimal parameters for the destruction of prostate cancer using irreversible electroporation.
Rubinsky J; Onik G; Mikus P; Rubinsky B
J Urol; 2008 Dec; 180(6):2668-74. PubMed ID: 18951581
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.
Park YH; Hwang IS; Jeong CW; Kim HH; Lee SE; Kwak C
J Urol; 2009 Jun; 181(6):2520-4; discussion 2525. PubMed ID: 19371894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
